2022
Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF
Yeoh S, Docherty K, Jhund P, Hammarstedt A, Inzucchi S, Kober L, Kosiborod M, Martinez F, Ponikowski P, Solomon S, Sattar N, Welsh P, Sabatine M, Morrow D, McMurray J. Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF. European Heart Journal 2022, 43: ehac544.833. DOI: 10.1093/eurheartj/ehac544.833.Peer-Reviewed Original ResearchBaseline ET-1 concentrationET-1 concentrationsBaseline ET-1Benefit of dapagliflozinSerum ET-1Kidney functionEndothelin-1Tertile 3NT-proBNPPrimary outcomeCirculating Endothelin-1DAPA-HF trialEfficacy of dapagliflozinET-1 measurementsHeart Failure TrialReduced ejection fractionWorse functional statusET-1 levelsHeart failure outcomesHeart failure severityHigh-sensitivity troponinDAPA-HFCardiovascular deathEGFR slopeLower eGFR
2015
A reappraisal of loop diuretic choice in heart failure patients
Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, O'Connor CM. A reappraisal of loop diuretic choice in heart failure patients. American Heart Journal 2015, 169: 323-333. PMID: 25728721, PMCID: PMC4346710, DOI: 10.1016/j.ahj.2014.12.009.Peer-Reviewed Original ResearchConceptsHeart failure patientsHeart failureFailure patientsLoop diureticsNew York Heart Association functional classPlasma brain natriuretic peptide levelsYork Heart Association functional classBrain natriuretic peptide levelsHeart failure severityNatriuretic peptide levelsTranscardiac extractionAldosterone secretionAldosterone systemDiuretic useVentricular functionFurosemide useSymptom managementPharmacologic differencesCardiac fibrosisSurrogate markerMEDLINE searchPeptide levelsControl trialEconomic burdenFurosemide
2007
Patterns of Weight Change Preceding Hospitalization for Heart Failure
Chaudhry SI, Wang Y, Concato J, Gill TM, Krumholz HM. Patterns of Weight Change Preceding Hospitalization for Heart Failure. Circulation 2007, 116: 1549-1554. PMID: 17846286, PMCID: PMC2892745, DOI: 10.1161/circulationaha.107.690768.Peer-Reviewed Original ResearchConceptsHeart failure hospitalizationHeart failureControl patientsFailure hospitalizationBody weightCase patientsWeight gainDecompensated heart failureHeart failure severityBaseline body weightHeart failure decompensationPatient's body weightAdjusted odds ratioCase-control studyGradual weight gainDisease management programsHigh-risk periodBasis of ageOdds ratioHospitalizationPatientsMean increaseDaily weightWeight changeHome monitoring
2005
The Relationship Between B-type Natriuretic Peptide and Health Status in Patients With Heart Failure
Luther SA, McCullough PA, Havranek EP, Rumsfeld JS, Jones PG, Heidenreich PA, Peterson ED, Rathore SS, Krumholz HM, Weintraub WS, Spertus JA, Masoudi FA, Consortium F. The Relationship Between B-type Natriuretic Peptide and Health Status in Patients With Heart Failure. Journal Of Cardiac Failure 2005, 11: 414-421. PMID: 16105631, DOI: 10.1016/j.cardfail.2005.02.004.Peer-Reviewed Original ResearchConceptsKansas City Cardiomyopathy QuestionnaireBNP levelsHeart failureHealth statusBNP changesB-type natriuretic peptide levelsNew York Heart Association classificationB-type natriuretic peptideBaseline BNP levelsKCCQ summary scoreNatriuretic peptide levelsHeart failure severitySystolic heart failureHealth status instrumentsBaseline BNPKCCQ scoresNatriuretic peptideAssociation classificationPatients' perceptionsPeptide levelsPhysiologic measuresSummary scoresPatientsBNPDisease severity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply